Table 4.
Open in new tab

Multivariable analysis comparing durability postexposure and durability postescalation.

HR (95% CI)P-valueHR (95% CI)P-value
Proactive vs reactive0.42 (0.25, 0.70).0010.44 (0.26, 0.74).002
Montreal classification—disease location
 L1—ilealRefRef
 L2—colonic0.74 (0.37, 1.46).3801.01 (0.51, 2.00).979
 L3—ileocolonic0.60 (0.32, 1.11).1010.77 (0.41, 1.42).400
 L4—isolated upper GI0.48 (0.06, 3.84).4911.18 (0.15, 9.41).875
Montreal classification—disease behavior
 B1—uncomplicatedRefRef
 B2—stricturing1.34 (0.73, 2.48).3481.10 (0.61, 1.97).759
 B3—penetrating2.10 (1.10, 3.98).0241.97 (1.05, 3.68).034
Perianal disease0.40 (0.24, 0.67)<.0010.35 (0.21, 0.58)<.001
Tumor Necrosis Factor Naïve0.63 (0.39, 1.01).0450.54 (0.33, 0.90).017
Concurrent immunomodulator use0.75 (0.48, 1.18).2120.71 (0.45, 1.14).155
HR (95% CI)P-valueHR (95% CI)P-value
Proactive vs reactive0.42 (0.25, 0.70).0010.44 (0.26, 0.74).002
Montreal classification—disease location
 L1—ilealRefRef
 L2—colonic0.74 (0.37, 1.46).3801.01 (0.51, 2.00).979
 L3—ileocolonic0.60 (0.32, 1.11).1010.77 (0.41, 1.42).400
 L4—isolated upper GI0.48 (0.06, 3.84).4911.18 (0.15, 9.41).875
Montreal classification—disease behavior
 B1—uncomplicatedRefRef
 B2—stricturing1.34 (0.73, 2.48).3481.10 (0.61, 1.97).759
 B3—penetrating2.10 (1.10, 3.98).0241.97 (1.05, 3.68).034
Perianal disease0.40 (0.24, 0.67)<.0010.35 (0.21, 0.58)<.001
Tumor Necrosis Factor Naïve0.63 (0.39, 1.01).0450.54 (0.33, 0.90).017
Concurrent immunomodulator use0.75 (0.48, 1.18).2120.71 (0.45, 1.14).155
Table 4.
Open in new tab

Multivariable analysis comparing durability postexposure and durability postescalation.

HR (95% CI)P-valueHR (95% CI)P-value
Proactive vs reactive0.42 (0.25, 0.70).0010.44 (0.26, 0.74).002
Montreal classification—disease location
 L1—ilealRefRef
 L2—colonic0.74 (0.37, 1.46).3801.01 (0.51, 2.00).979
 L3—ileocolonic0.60 (0.32, 1.11).1010.77 (0.41, 1.42).400
 L4—isolated upper GI0.48 (0.06, 3.84).4911.18 (0.15, 9.41).875
Montreal classification—disease behavior
 B1—uncomplicatedRefRef
 B2—stricturing1.34 (0.73, 2.48).3481.10 (0.61, 1.97).759
 B3—penetrating2.10 (1.10, 3.98).0241.97 (1.05, 3.68).034
Perianal disease0.40 (0.24, 0.67)<.0010.35 (0.21, 0.58)<.001
Tumor Necrosis Factor Naïve0.63 (0.39, 1.01).0450.54 (0.33, 0.90).017
Concurrent immunomodulator use0.75 (0.48, 1.18).2120.71 (0.45, 1.14).155
HR (95% CI)P-valueHR (95% CI)P-value
Proactive vs reactive0.42 (0.25, 0.70).0010.44 (0.26, 0.74).002
Montreal classification—disease location
 L1—ilealRefRef
 L2—colonic0.74 (0.37, 1.46).3801.01 (0.51, 2.00).979
 L3—ileocolonic0.60 (0.32, 1.11).1010.77 (0.41, 1.42).400
 L4—isolated upper GI0.48 (0.06, 3.84).4911.18 (0.15, 9.41).875
Montreal classification—disease behavior
 B1—uncomplicatedRefRef
 B2—stricturing1.34 (0.73, 2.48).3481.10 (0.61, 1.97).759
 B3—penetrating2.10 (1.10, 3.98).0241.97 (1.05, 3.68).034
Perianal disease0.40 (0.24, 0.67)<.0010.35 (0.21, 0.58)<.001
Tumor Necrosis Factor Naïve0.63 (0.39, 1.01).0450.54 (0.33, 0.90).017
Concurrent immunomodulator use0.75 (0.48, 1.18).2120.71 (0.45, 1.14).155
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close